Paraguay Medical Device Registration 2026: Spanish Labelling and Instructions for Use
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
- Article 6, item g) requires that labels and instructions for use be translated into Spanish (rotulado e instrucciones de uso).
- The label content (Article 19) must state: the manufacturer, the importer and the distributor (where applicable), the technical responsible party, and the approved conditions of sale, together with the wording AUTORIZADO POR DINAVISA and the number of the sanitary registration certificate or the NSO.
- A complementary label (etiqueta complementaria) is permitted, but its content may only add to or supplement the main label; it must not repeat what the main label already states.
- When a label change is filed, the operating instructions Article 14 require the current label draft and the updated draft to be submitted simultaneously on DINAVISAPy, with the declared modifications marked within the same document.
- The wording AUTORIZADO POR DINAVISA is not decorative: it is the marker that connects the physical product to the registration record, and a label without it, or with an inconsistent certificate number, is treated as an unregistered presentation of the product.
2. Legal basis
| Instrument | Number / reference | Date | Provision |
|---|---|---|---|
| Resolution on market authorization requirements for medical devices | Resolución DINAVISA N° 226/2024 | 2024-08-27; Article 36 in force from 2024-09-16 | Article 6, item g); Article 19; Article 25 |
| Operating instructions and guide for submitting applications | Instructivo ITR–DGRS-002, Versión 02 | 2024-09-09 | Article 14; Article 15 |
The resolution carries the substantive labelling obligations, from the Spanish language requirement in item g) to the mandatory content in Article 19, while the operating instructions govern the mechanics of label-related filings through Articles 14 and 15, including how complementary labels may be used and how change submissions must present the two drafts. Article 25 of the resolution reinforces the framework by tying the label back to the registered presentation of the product, which is why labelling evidence is checked both at filing and whenever a change touches the label. A label that drifts from the registration record creates a mismatch that surfaces in the most inconvenient places: import clearance, distribution audits and post-market inspection. Because the mandatory content is fixed, the design freedom lies in layout and language, not in what the label must carry.
3. Expert insights
Insight one: the label is the physical carrier of the registration decision, and any change to it is a change matter. The label carries the approved conditions of sale and the certificate number, both of which are elements of the registration decision itself. A label redesign is therefore never a pure packaging exercise; it must be routed back through the change classification of Article 13: changes that are purely visual and leave the technical information untouched fall into Class I changes and may be implemented immediately, while changes that affect technical information or the conditions of sale fall into Class II changes and require approval before implementation. The classification decision should therefore be documented at the moment the change is designed, with the reasons recorded, so that the implementation timing is defensible if the reviewer later disagrees.
Insight two: the rule that a complementary label must not repeat the main label is often misread as permission to cover. Article 15 of the operating instructions states that the complementary label may only provide additional or supplementary information and must not duplicate the main label. In practice, using a complementary label to cover non-conforming elements of the English original label of the country of manufacture is a non-compliant shortcut; the correct path is to redesign the main label itself in its Spanish version, so that the mandatory content of Article 19 appears on a single, self-consistent label. The complementary label remains useful for genuine additions, such as extra languages or distributor details, precisely because it supplements rather than replaces.
Insight three: the two-draft comparison required for change filings is a review-friendly design, and ignoring it is costly. Article 14 requires the current draft and the updated draft to be submitted together, with the modifications marked inside the same document, so that the reviewer can perform a direct difference comparison. Companies that upload the two drafts as separate files or omit the marking will receive a deficiency and spend one rectification window of 60 business days repairing a formatting issue rather than a technical one. Preparing the marking inside the same file is a formatting discipline best fixed in the template used by the graphics team, so that every label change inherits it automatically.
4. Practical recommendations
- During label design, fix the block containing the approved conditions of sale, the wording AUTORIZADO POR DINAVISA and the certificate number as a permanent zone that does not move with marketing redesigns, so that marketing teams never relocate the regulatory zone during artwork updates.
- Produce the main label directly in its Spanish version, and never use a complementary label to cover English content.
- Assemble label change submissions as a single document containing the current draft, the updated draft and the modification markings, using a marked-up master copy rather than a free-text cover note.
- Classify every label change before filing: Class I changes may be implemented immediately, while Class II changes must wait for approval after the 45-business-day evaluation period, and the evidence of the classification decision should be kept with the change record.
- Keep a controlled master copy of the Spanish label in the regulatory file, so that every printed version can be traced back to an approved draft during audits.
5. Verification checklist
- □ Label and instructions for use fully translated into Spanish
- □ Label states the manufacturer, importer / distributor, technical responsible party and conditions of sale
- □ Label carries the wording AUTORIZADO POR DINAVISA and the certificate number
- □ Complementary label contains only additional information and does not repeat the main label
- □ Label change filed as a single document with the current draft, updated draft and markings
Regulatory information verified as of October 29, 2026.
GRZAN provides registration and conformity support in Paraguay for medical device manufacturers, importers and authorized representatives, including Spanish labelling design and change classification under Article 13. For assistance, contact info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us